Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study.
about
Position Statement: Drug Holiday in Osteoporosis Treatment with Bisphosphonates in South KoreaNew insights into treatment of osteoporosis in postmenopausal womenManaging Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral ResearchA model of BMD changes after alendronate discontinuation to guide postalendronate BMD monitoringUK clinical guideline for the prevention and treatment of osteoporosisClinician's Guide to Prevention and Treatment of OsteoporosisProtocol for a randomized controlled trial to compare bone-loading exercises with risedronate for preventing bone loss in osteopenic postmenopausal womenFavorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate.Bone turnover biomarkers and risk of osteoporotic hip fracture in an Asian populationSerum Markers of Bone Turnover and Angiogenesis in Patients With Bisphosphonate-Related Osteonecrosis of the Jaw After Discontinuation of Long-Term Intravenous Bisphosphonate Therapy.Short-term and long-term effects of osteoporosis therapies.The use of bisphosphonates in women: when to use and when to stop.Bisphosphonate drug holidays--when, why and for how long?Effects of Long-Term Low-Molecular-Weight Heparin on Fractures and Bone Density in Non-Pregnant Adults: A Systematic Review With Meta-Analysis.Review: Breaking From Bisphosphonates.Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease.The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis.A 7-Year Longitudinal Trial of the Safety and Efficacy of a Vitamin/Mineral Enhanced Plant-Sourced Calcium Supplement.Management of oral bisphosphonates treatment by rheumatologists and determinants of therapeutic changes: a case-vignette-based study.Changes in bone mineral density and bone turnover in patients on 'drug holiday' following bisphosphonate therapy: real-life clinic setting.Correlation between tibial measurements using peripheral quantitative computed tomography and hip areal bone density measurements in ambulatory chronic stroke patients.Atypical femoral fractures bilaterally in a patient receiving bisphosphonate: a case report.Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk.Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.Bisphosphonate guidelines for treatment and prevention of myeloma bone disease.Osteoporosis: A Review of Treatment Options.Low Plasma Level of Leucine-Rich Repeat-Containing 17 (LRRc17) Is an Independent and Additive Risk Factor for Osteoporotic Fractures in Postmenopausal Women.
P2860
Q26771713-E3005F01-EDAB-4356-A141-EAC24DF7F76FQ26777910-4BF61D59-5BD5-4342-BFD3-1DD6AB7CD990Q26782621-3413A8A2-860C-4BFC-A1A7-2BE8FB9318B0Q33570209-F1C61D39-5A69-496C-B8CE-81A451486E1DQ33581078-A2295010-9CDF-4D4E-9D45-6668ADCC8960Q34250632-5784A24D-F56E-4972-9E8F-E2902ED2B2E2Q36117213-503072CA-B73E-407D-BEF8-48AAB434AB12Q36356633-8209A8CA-75F2-4105-88F0-3C96B305704DQ36494036-28F86B53-ED5A-45DD-8572-3A8F88A9366DQ37009387-4AA1FA89-FF57-404E-BB51-104FA580E95BQ38473594-1AE9DFAB-2BCD-401A-A5E9-FE90036438B4Q38584336-BC9B2292-1045-450F-B42C-7EA6219F78FBQ38617760-64D958F8-76FC-41DB-B71C-08396B748EFCQ38741507-2FCA0C7D-50C1-41BB-B874-5C7B9CBEE87CQ38992765-150D031E-6BD3-47FC-AEE5-EC3F6A8AA9EBQ39035413-4559B71D-4DCC-4875-9DEC-8DC448731431Q39975608-1A8195BE-600F-464D-BD91-FBA0AF642B1FQ39991176-83BFA283-4F45-4464-9330-9A88D3B86B73Q40065539-493E5B3A-ADBE-4432-A667-ADD83964B253Q40160557-C891D39A-CF97-402E-B32B-23FDA38063F3Q40232040-259C6C38-19D9-42D5-9A6B-72C7C3E0C042Q42113291-5A332E1F-7CD5-4B9E-A3E6-9140C9270D0AQ47279165-DC758B57-839F-4A66-A252-B7ED86211CB3Q48069145-C44B01DE-49CF-4C01-BA42-EBAE473390B8Q48283228-7EECFCEE-85A2-4F49-BA10-35C75D1FB2BBQ49540487-A0CD7F48-E3DD-45F1-9A6C-A0390BCE360FQ51674576-D2E17571-8944-4CA9-9E80-BE02878FCE1A
P2860
Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Fracture prediction after disc ...... onate therapy: the FLEX study.
@ast
Fracture prediction after disc ...... onate therapy: the FLEX study.
@en
type
label
Fracture prediction after disc ...... onate therapy: the FLEX study.
@ast
Fracture prediction after disc ...... onate therapy: the FLEX study.
@en
prefLabel
Fracture prediction after disc ...... onate therapy: the FLEX study.
@ast
Fracture prediction after disc ...... onate therapy: the FLEX study.
@en
P2093
P2860
P1476
Fracture prediction after disc ...... onate therapy: the FLEX study.
@en
P2093
Ann Schwartz
Art Santora
Dennis M Black
Douglas C Bauer
Lisa Palermo
Marc Hochberg
Steven R Cummings
P2860
P304
P356
10.1001/JAMAINTERNMED.2014.1232
P577
2014-07-01T00:00:00Z